多价免疫球蛋白用于甲型肝炎、风疹和麻疹暴露后预防的适应证和安全性。
The indications and safety of polyvalent immunoglobulin for post-exposure prophylaxis of hepatitis A, rubella and measles.
机构信息
School of Medicine and Menzies Health Institute Queensland, Griffith University , Brisbane , Australia.
出版信息
Hum Vaccin Immunother. 2019;15(9):2060-2065. doi: 10.1080/21645515.2019.1621148. Epub 2019 Jun 19.
Abstract
Derived from pooled blood donations, polyvalent immunoglobulins are used for post-exposure prophylaxis as one aspect of the public health management of hepatitis A, rubella and measles. This review summarizes the safety profile of these blood products and the current recommendations for their use for the prevention of hepatitis A, rubella and measles among people who have been exposed to these diseases. The current recommendations are drawn from the most recent publicly available national guidelines of the United States, Australia, New Zealand, Canada and the United Kingdom as accessed in February 2019.
摘要
从混合献血中提取的多价免疫球蛋白，作为甲型肝炎、风疹和麻疹公共卫生管理的一个方面，用于暴露后预防。本综述总结了这些血液制品的安全性概况以及目前针对已接触这些疾病的人群预防甲型肝炎、风疹和麻疹的使用建议。这些建议来自于 2019 年 2 月可获取的最新美国、澳大利亚、新西兰、加拿大和英国国家指南。
相似文献
1
The indications and safety of polyvalent immunoglobulin for post-exposure prophylaxis of hepatitis A, rubella and measles.多价免疫球蛋白用于甲型肝炎、风疹和麻疹暴露后预防的适应证和安全性。
Hum Vaccin Immunother. 2019;15(9):2060-2065. doi: 10.1080/21645515.2019.1621148. Epub 2019 Jun 19.
2
The optimal dose of disease-specific antibodies for post-exposure prophylaxis of measles and rubella in Australia: new guidelines recommended.澳大利亚推荐了新的指南，用于确定麻疹和风疹暴露后预防的疾病特异性抗体的最佳剂量。
Expert Opin Drug Metab Toxicol. 2018 Jul;14(7):663-669. doi: 10.1080/17425255.2018.1484449.
3
Passive immunization for the public health control of communicable diseases: current status in four high-income countries and where to next.用于传染病公共卫生控制的被动免疫：四个高收入国家的现状及未来走向。
Hum Vaccin Immunother. 2013 Sep;9(9):1885-93. doi: 10.4161/hv.25311. Epub 2013 Jun 19.
4
Post-exposure prophylaxis for measles with immunoglobulins revised recommendations of the standing committee on vaccination in Germany.接触后用免疫球蛋白预防麻疹——德国疫苗接种常设委员会的修订建议。
Vaccine. 2018 Dec 18;36(52):7916-7922. doi: 10.1016/j.vaccine.2018.10.070. Epub 2018 Nov 23.
5
6
Do Australian immunoglobulin products meet international measles antibody titer standards?澳大利亚的免疫球蛋白产品是否符合国际麻疹抗体滴度标准？
Hum Vaccin Immunother. 2017 Mar 4;13(3):607-612. doi: 10.1080/21645515.2016.1234554. Epub 2016 Oct 20.
7
Pharmacokinetic modeling to determine the minimum effective dose of disease-specific antibodies for preventing hepatitis A post-exposure.药代动力学建模以确定预防甲型肝炎暴露后感染的疾病特异性抗体的最小有效剂量。
Expert Opin Drug Metab Toxicol. 2020 Jul;16(7):641-644. doi: 10.1080/17425255.2020.1763303. Epub 2020 May 3.
8
Rubella antibodies in Australian immunoglobulin products.澳大利亚免疫球蛋白产品中的风疹抗体。
Hum Vaccin Immunother. 2017 Aug 3;13(8):1952-1955. doi: 10.1080/21645515.2017.1327110. Epub 2017 Jun 12.
9
[Indications for the use of normal immunoglobulins and of specific immunoglobulins].[正常免疫球蛋白和特异性免疫球蛋白的使用指征]
Tidsskr Nor Laegeforen. 1983 Jan 30;103(3):222-4.
10
Passive immunization with gamma globulin.用丙种球蛋白进行被动免疫。
J Occup Med. 1966 Nov;8(11):567-72.
引用本文的文献
1
Regional and age related variations in hepatitis A virus incidence in China 2004 to 2018: a descriptive epidemiological study.2004年至2018年中国甲型肝炎病毒发病率的地区和年龄相关差异：一项描述性流行病学研究
Sci Rep. 2025 Jun 2;15(1):19230. doi: 10.1038/s41598-025-03649-6.
2
Serosurveillance for Measles and Rubella.麻疹和风疹血清学监测
Vaccines (Basel). 2024 Jul 22;12(7):816. doi: 10.3390/vaccines12070816.
3
Current perspectives of viral hepatitis.病毒性肝炎的研究现状。
World J Gastroenterol. 2024 May 14;30(18):2402-2417. doi: 10.3748/wjg.v30.i18.2402.
4
Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trial.皮下注射抗COVID-19超免疫球蛋白预防SARS-CoV-2感染无症状个体发病：一项双盲、安慰剂对照、随机临床试验。
EClinicalMedicine. 2023 Mar 10;57:101898. doi: 10.1016/j.eclinm.2023.101898. eCollection 2023 Mar.
5
Biological Profile and Clinical Features as Determinants for Prolonged Hospitalization in Adult Patients with Measles: A Monocentric Study in Western Romania.麻疹成年患者长期住院的生物学特征和临床特征决定因素：罗马尼亚西部的一项单中心研究
Pathogens. 2022 Sep 7;11(9):1018. doi: 10.3390/pathogens11091018.
6
Repurposing an In Vitro Measles Virus Dissemination Assay for Screening of Antiviral Compounds.重新利用麻疹病毒体外传播检测法筛选抗病毒化合物。
Viruses. 2022 May 29;14(6):1186. doi: 10.3390/v14061186.
7
Subacute Sclerosing Panencephalitis in Children: The Archetype of Non-Vaccination.儿童亚急性硬化性全脑炎：非接种疫苗的典型范例。
Viruses. 2022 Mar 31;14(4):733. doi: 10.3390/v14040733.
8
Nanomedicine: A Diagnostic and Therapeutic Approach to COVID-19.纳米医学：一种针对新冠病毒病的诊断与治疗方法
Front Med (Lausanne). 2021 Jun 4;8:648005. doi: 10.3389/fmed.2021.648005. eCollection 2021.
9
Convalescent Plasma Therapy for Management of COVID-19: Perspectives and Deployment in the Current Global Pandemic.用于治疗新型冠状病毒肺炎的恢复期血浆疗法：当前全球大流行中的观点与应用
Risk Manag Healthc Policy. 2020 Nov 23;13:2707-2728. doi: 10.2147/RMHP.S281388. eCollection 2020.
10
Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization.针对严重急性呼吸综合征冠状病毒 2 型的抗体及其在治疗性被动免疫中的潜在作用。
Elife. 2020 Jun 23;9:e57877. doi: 10.7554/eLife.57877.
本文引用的文献
1
What is new in the Canadian Immunization Guide: November 2016 to November 2018.《加拿大免疫指南》2016年11月至2018年11月的新内容。
Can Commun Dis Rep. 2018 Dec 6;44(12):331-335. doi: 10.14745/ccdr.v44i12a06.
2
Updated NACI recommendations for measles post-exposure prophylaxis.加拿大国家免疫咨询委员会（NACI）关于麻疹暴露后预防的最新建议。
Can Commun Dis Rep. 2018 Sep 6;44(9):226-230. doi: 10.14745/ccdr.v44i09a07.
3
Update: Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel.更新：免疫实践咨询委员会关于使用甲型肝炎疫苗进行接触后预防和国际旅行接触前预防的建议。
MMWR Morb Mortal Wkly Rep. 2018 Nov 2;67(43):1216-1220. doi: 10.15585/mmwr.mm6743a5.
4
The optimal dose of disease-specific antibodies for post-exposure prophylaxis of measles and rubella in Australia: new guidelines recommended.澳大利亚推荐了新的指南，用于确定麻疹和风疹暴露后预防的疾病特异性抗体的最佳剂量。
Expert Opin Drug Metab Toxicol. 2018 Jul;14(7):663-669. doi: 10.1080/17425255.2018.1484449.
5
Updated Dosing Instructions for Immune Globulin (Human) GamaSTAN S/D for Hepatitis A Virus Prophylaxis.用于甲型肝炎病毒预防的人免疫球蛋白GamaSTAN S/D的更新给药说明。
MMWR Morb Mortal Wkly Rep. 2017 Sep 15;66(36):959-960. doi: 10.15585/mmwr.mm6636a5.
6
Rubella antibodies in Australian immunoglobulin products.澳大利亚免疫球蛋白产品中的风疹抗体。
Hum Vaccin Immunother. 2017 Aug 3;13(8):1952-1955. doi: 10.1080/21645515.2017.1327110. Epub 2017 Jun 12.
7
Evaluation of Potencies of Immune Globulin Products Against Hepatitis A.免疫球蛋白产品抗甲型肝炎效力的评估
JAMA Intern Med. 2017 Mar 1;177(3):430-432. doi: 10.1001/jamainternmed.2016.9057.
8
Do Australian immunoglobulin products meet international measles antibody titer standards?澳大利亚的免疫球蛋白产品是否符合国际麻疹抗体滴度标准？
Hum Vaccin Immunother. 2017 Mar 4;13(3):607-612. doi: 10.1080/21645515.2016.1234554. Epub 2016 Oct 20.
9
Management of adverse events in the treatment of patients with immunoglobulin therapy: A review of evidence.免疫球蛋白治疗患者不良反应的处理：证据综述。
Autoimmun Rev. 2016 Jan;15(1):71-81. doi: 10.1016/j.autrev.2015.09.002. Epub 2015 Sep 16.
10
Post-exposure passive immunisation for preventing rubella and congenital rubella syndrome.暴露后被动免疫预防风疹和先天性风疹综合征。
Cochrane Database Syst Rev. 2015 Sep 9;2015(9):CD010586. doi: 10.1002/14651858.CD010586.pub2.
Zotero 插件